Biotheranostics was acquired by Hologic in February 2021, and continues to offer its portfolio of proprietary genomic assays to support personalized disease management in oncology. Visit Hologic.com.


Biotheranostics was acquired by Hologic in February 2021, and continues to offer its portfolio of proprietary genomic assays to support personalized disease management in oncology. Visit Hologic.com.



BREAST CANCER INDEX

The only genomic test recognized by ASCO® and NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to help predict benefit of extended endocrine therapy in HR+, early-stage breast cancer. 1,2


CANCERTYPE ID®

The most validated gene expression based assay to help identify the tumor type and subtype for metastatic cancer patients with unknown or unclear diagnoses.


1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 27, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way 2. Andre F et al. J Clin Oncol. Published online April 19, 2022. DOI: 10.1200/JCO.22.00069

Hologic, Biotheranostics, Breast Cancer Index, CancerTYPE ID and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks and product names are the property of their respective owners.